EUR 0.0
(0.0%)
Year | Inventory | Inventory Growth |
---|---|---|
2023 | - EUR | 0.0% |
2022 | - EUR | -100.0% |
2021 | 2.21 Million EUR | 0.0% |
2020 | - EUR | -100.0% |
2019 | 1000.00 EUR | 0.0% |
2018 | - EUR | -100.0% |
2017 | 1000.00 EUR | 200.0% |
2016 | -1000.00 EUR | -200.0% |
2015 | 1000.00 EUR | 0.0% |
2014 | - EUR | 0.0% |
2013 | - EUR | 0.0% |
2012 | - EUR | 0.0% |
2011 | - EUR | 0.0% |
Year | Inventory | Inventory Growth |
---|---|---|
2024 Q1 | - EUR | 0.0% |
2024 Q2 | - EUR | 0.0% |
2023 Q4 | - EUR | 0.0% |
2023 Q3 | - EUR | 0.0% |
2023 FY | - EUR | 0.0% |
2023 Q1 | - EUR | 0.0% |
2023 Q2 | - EUR | 0.0% |
2022 Q4 | - EUR | 0.0% |
2022 FY | - EUR | -100.0% |
2022 Q2 | - EUR | 0.0% |
2022 Q3 | - EUR | 0.0% |
2021 Q2 | 1000.00 EUR | 0.0% |
2021 Q4 | -1000.00 EUR | 0.0% |
2021 FY | 2.21 Million EUR | 0.0% |
2020 FY | - EUR | -100.0% |
2020 Q4 | - EUR | 0.0% |
2020 Q2 | - EUR | 0.0% |
2019 Q4 | 1000.00 EUR | 0.0% |
2019 Q2 | - EUR | 0.0% |
2019 FY | 1000.00 EUR | 0.0% |
2018 Q2 | - EUR | 0.0% |
2018 FY | - EUR | -100.0% |
2018 Q4 | - EUR | 0.0% |
2017 Q4 | - EUR | 0.0% |
2017 FY | 1000.00 EUR | 200.0% |
2017 Q2 | - EUR | 0.0% |
2016 Q2 | - EUR | 0.0% |
2016 Q4 | - EUR | 0.0% |
2016 FY | -1000.00 EUR | -200.0% |
2015 Q2 | - EUR | 0.0% |
2015 Q4 | - EUR | 0.0% |
2015 FY | 1000.00 EUR | 0.0% |
2014 Q4 | - EUR | 0.0% |
2014 Q3 | - EUR | 0.0% |
2014 FY | - EUR | 0.0% |
2013 FY | - EUR | 0.0% |
2013 Q4 | - EUR | 0.0% |
2012 FY | - EUR | 0.0% |
2011 FY | - EUR | 0.0% |
Name | Inventory | Inventory Difference |
---|---|---|
Nicox S.A. | - EUR | NaN% |
European Medical Solutions | 14.35 Million EUR | 100.0% |
FERMENTALG | 6.8 Million EUR | 100.0% |
argenx SE | 281.12 Million EUR | 100.0% |
Celyad Oncology SA | 1.26 Million EUR | 100.0% |
Hyloris Pharmaceuticals SA | 1.00 EUR | 100.0% |
Onward Medical N.V. | 936 Thousand EUR | 100.0% |
Oxurion NV | 128 Thousand EUR | 100.0% |
PHAXIAM Therapeutics S.A. | 671 Thousand EUR | 100.0% |
Financière de Tubize SA | - EUR | NaN% |
UCB SA | 1.03 Billion EUR | 100.0% |